Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Iacobas, Ionela
EPIK-L1, NCT05948943: Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.	Recruiting	2/3	230	Europe, US, RoW	Alpelisib, BYL719, Placebo	Novartis Pharmaceuticals	Lymphatic Malformations	10/27	05/30
EPIK-P2, NCT04589650 / 2020-000561-16: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum	Recruiting	2	205	Europe, Canada, US, RoW	Alpelisib, Placebo	Novartis Pharmaceuticals	PIK3CA-related Overgrowth Spectrum (PROS)	03/24	04/31